See more : Acumen Pharmaceuticals, Inc. (ABOS) Income Statement Analysis – Financial Results
Complete financial analysis of H.U. Group Holdings, Inc. (4544.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of H.U. Group Holdings, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Phil-Good Products, Inc (PHGD) Income Statement Analysis – Financial Results
- ARDEPRO Co., Ltd. (8925.T) Income Statement Analysis – Financial Results
- BSR Real Estate Investment Trust (BSRTF) Income Statement Analysis – Financial Results
- The Hong Kong and China Gas Company Limited (0003.HK) Income Statement Analysis – Financial Results
- GFL Environmental Inc. (GFLU) Income Statement Analysis – Financial Results
H.U. Group Holdings, Inc. (4544.T)
About H.U. Group Holdings, Inc.
H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosmetic testing services; and testing services through corporate health insurance associations. It also researches, develops, manufactures, and sells in vitro diagnostic devices, which includes the LUMIPULSE, an automatic chemiluminescent enzyme immunoassay system that offers reagents for infectious disease, cancer, and lifestyle disease to medical institutions and testing centers; and ESPRINE, a rapid diagnostics kit series for influenza, hepatitis B, and the novel coronavirus, as well as supplies ingredients for test drugs. In addition, the company provides support services related to hospital administration work, including aid for surgical procedures and endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services; and rents and sells nursing-care equipment and supplies. Further, it offers home-visit nursing care services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.95B | 260.91B | 272.94B | 223.02B | 188.71B | 181.42B | 195.40B | 204.25B | 211.74B | 204.67B | 203.37B | 192.21B | 175.39B | 165.74B | 149.07B | 145.34B | 143.30B | 137.21B | 138.36B |
| Cost of Revenue | 173.72B | 170.98B | 161.15B | 146.81B | 131.14B | 119.46B | 122.95B | 124.56B | 130.33B | 124.27B | 120.68B | 115.69B | 107.99B | 104.31B | 93.43B | 94.36B | 92.06B | 86.95B | 84.88B |
| Gross Profit | 63.24B | 89.92B | 111.80B | 76.21B | 57.58B | 61.95B | 72.45B | 79.68B | 81.41B | 80.40B | 82.69B | 76.52B | 67.40B | 61.42B | 55.64B | 50.98B | 51.24B | 50.25B | 53.48B |
| Gross Profit Ratio | 26.69% | 34.47% | 40.96% | 34.17% | 30.51% | 34.15% | 37.08% | 39.01% | 38.45% | 39.28% | 40.66% | 39.81% | 38.43% | 37.06% | 37.32% | 35.08% | 35.76% | 36.63% | 38.65% |
| Research & Development | 11.26B | 9.56B | 7.28B | 5.94B | 5.51B | 5.94B | 5.37B | 4.75B | 5.70B | 5.38B | 5.41B | 5.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.05B | 51.57B | 51.18B | 42.09B | 39.42B | 38.90B | 45.08B | 40.60B | 41.88B | 40.05B | 43.35B | 39.37B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 5.97B | -141.00M | -1.78B | 553.00M | -30.00M | 13.00M | 109.00M | -58.00M | 208.00M | -565.00M | 562.00M | 539.00M | 284.00M | 427.00M | 401.00M | 611.00M | 418.00M | 446.00M | 336.00M |
| Operating Expenses | 67.28B | 66.54B | 61.31B | 50.82B | 47.64B | 47.30B | 54.80B | 51.63B | 55.36B | 53.38B | 55.96B | 50.92B | 44.18B | 40.10B | 35.83B | 36.05B | 36.45B | 35.73B | 336.00M |
| Cost & Expenses | 240.99B | 237.53B | 222.45B | 197.62B | 178.77B | 166.77B | 177.75B | 176.19B | 185.69B | 177.65B | 176.64B | 166.61B | 152.17B | 144.41B | 129.27B | 130.41B | 128.50B | 122.68B | 84.88B |
| Interest Income | 454.00M | 242.00M | 45.00M | 150.00M | 109.00M | 88.00M | 62.00M | 45.00M | 30.00M | 21.00M | 32.00M | 25.00M | 39.00M | 28.00M | 22.00M | 49.00M | 95.00M | 67.00M | 88.00M |
| Interest Expense | 399.00M | 369.00M | 395.00M | 309.00M | 230.00M | 195.00M | 334.00M | 484.00M | 607.00M | 589.00M | 514.00M | 559.00M | 282.00M | 88.00M | 24.00M | 42.00M | 74.00M | 109.00M | 140.00M |
| Depreciation & Amortization | 20.87B | 19.69B | 14.63B | 12.49B | 11.33B | 9.70B | 9.64B | 13.12B | 14.99B | 15.24B | 14.59B | 14.14B | 12.48B | 10.92B | 9.61B | 10.99B | 9.65B | 9.05B | 8.91B |
| EBITDA | 13.65B | 43.08B | 65.12B | 37.89B | 21.27B | 24.35B | 2.89B | 41.18B | 41.04B | 40.29B | 41.32B | 39.48B | 34.83B | 30.28B | 28.97B | 25.80B | 23.91B | 23.53B | 22.01B |
| EBITDA Ratio | 5.76% | 16.02% | 22.51% | 16.57% | 9.55% | 11.60% | 27.64% | 19.58% | 18.60% | 20.71% | 20.76% | 21.05% | 20.60% | 19.70% | 20.01% | 18.40% | 17.57% | 17.64% | 45.47% |
| Operating Income | -4.04B | 23.38B | 50.49B | 25.39B | 9.94B | 14.65B | 17.65B | 28.06B | 26.05B | 27.01B | 26.73B | 25.60B | 23.22B | 21.33B | 19.81B | 14.93B | 14.80B | 14.53B | 13.28B |
| Operating Income Ratio | -1.71% | 8.96% | 18.50% | 11.39% | 5.27% | 8.07% | 9.03% | 13.74% | 12.30% | 13.20% | 13.14% | 13.32% | 13.24% | 12.87% | 13.29% | 10.27% | 10.32% | 10.59% | 9.60% |
| Total Other Income/Expenses | -3.58B | -474.00M | -9.17B | -4.57B | -3.83B | -3.27B | -24.73B | -23.62B | -22.45B | -2.68B | -597.00M | -656.00M | -1.15B | -2.05B | -473.00M | -162.00M | -612.00M | -149.00M | -330.00M |
| Income Before Tax | -7.62B | 22.91B | 41.32B | 20.82B | 6.11B | 11.38B | -7.08B | 4.44B | 3.60B | 24.33B | 26.13B | 24.94B | 22.07B | 19.28B | 19.34B | 14.77B | 14.18B | 14.38B | 12.95B |
| Income Before Tax Ratio | -3.22% | 8.78% | 15.14% | 9.34% | 3.24% | 6.27% | -3.62% | 2.17% | 1.70% | 11.89% | 12.85% | 12.98% | 12.58% | 11.63% | 12.97% | 10.16% | 9.90% | 10.48% | 9.36% |
| Income Tax Expense | -66.00M | 7.23B | 11.71B | 3.40B | 6.63B | 4.99B | -7.34B | 4.11B | 8.68B | 8.33B | 10.81B | 10.07B | 9.76B | 8.11B | 7.74B | 6.02B | 5.86B | 5.91B | 4.87B |
| Net Income | -7.55B | 15.68B | 29.60B | 17.47B | -516.00M | 6.39B | 257.00M | 333.00M | -5.08B | 16.00B | 15.32B | 14.87B | 12.31B | 11.17B | 11.59B | 8.71B | 8.30B | 8.45B | 8.06B |
| Net Income Ratio | -3.19% | 6.01% | 10.84% | 7.83% | -0.27% | 3.52% | 0.13% | 0.16% | -2.40% | 7.82% | 7.53% | 7.74% | 7.02% | 6.74% | 7.77% | 5.99% | 5.79% | 6.16% | 5.83% |
| EPS | -132.77 | 275.51 | 519.54 | 306.38 | -9.06 | 111.94 | 4.50 | 5.84 | -89.20 | 274.82 | 261.48 | 254.92 | 211.33 | 191.93 | 199.06 | 148.64 | 137.61 | 140.40 | 135.91 |
| EPS Diluted | -132.77 | 275.49 | 519.42 | 306.32 | -9.06 | 111.91 | 4.50 | 5.84 | -89.20 | 274.32 | 260.80 | 254.39 | 210.99 | 191.75 | 199.03 | 148.64 | 137.42 | 140.07 | 133.73 |
| Weighted Avg Shares Out | 56.89M | 56.90M | 56.97M | 57.01M | 56.97M | 57.05M | 57.07M | 57.01M | 56.96M | 58.23M | 58.60M | 58.34M | 58.26M | 58.22M | 58.21M | 58.59M | 60.30M | 60.17M | 59.34M |
| Weighted Avg Shares Out (Dil) | 56.89M | 56.90M | 56.99M | 57.03M | 56.97M | 57.06M | 57.07M | 57.01M | 56.96M | 58.33M | 58.75M | 58.46M | 58.35M | 58.27M | 58.22M | 58.59M | 60.38M | 60.31M | 60.30M |
Source: https://incomestatements.info
Category: Stock Reports